Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline
Open Access
- 6 September 2013
- journal article
- review article
- Published by S. Karger AG in Nephron Clinical Practice
- Vol. 124 (1-2), 1-9
- https://doi.org/10.1159/000354711
Abstract
Bone disease and ectopic calcification are the two main consequences of hyperphosphataemia of chronic kidney disease (CKD). Observational studies have demonstrated that hyperphosphataemia in CKD is associated with increased mortality. Furthermore, the use of phosphate binders in dialysis patients is associated with significantly lower mortality. The UK Renal Registry data show significant underachievement of phosphate targets in dialysis patients. It is believed to be due to wide variation in how management interventions are used. The National Institute for Health and Clinical Excellence (NICE) has developed a guideline on the management of hyperphosphataemia in CKD. This is based on the evidence currently available using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. This review outlines the recommendations including research recommendations and discusses methodology, rationale and challenges faced in developing this guideline and the health economic model used to assess the cost-effectiveness of different phosphate binders.Keywords
This publication has 51 references indexed in Scilit:
- Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?BMC Nephrology, 2011
- Direct Effects of Phosphate on Vascular Cell FunctionAdvances in Chronic Kidney Disease, 2011
- A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney diseaseBMC Nephrology, 2011
- Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerabilityNephrology Dialysis Transplantation, 2010
- Hyperphosphatemia of chronic kidney diseaseKidney International, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney diseaseNephrology Dialysis Transplantation, 2008
- Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trialInternational Urology and Nephrology, 2008
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004